- Home
- MGNX vs BZFD Comparison
MGNX vs BZFD Comparison
Compare MGNX & BZFD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- BZFD
- Stock Information
- Founded
- MGNX 2000
- BZFD 2006
- Country
- MGNX United States
- BZFD United States
- Employees
- MGNX N/A
- BZFD N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- BZFD Movies/Entertainment
- Sector
- MGNX Health Care
- BZFD Consumer Discretionary
- Exchange
- MGNX Nasdaq
- BZFD Nasdaq
- Market Cap
- MGNX 70.3M
- BZFD 65.1M
- IPO Year
- MGNX 2013
- BZFD N/A
- Fundamental
- Price
- MGNX $1.26
- BZFD $1.73
- Analyst Decision
- MGNX Hold
- BZFD
- Analyst Count
- MGNX 10
- BZFD 0
- Target Price
- MGNX $6.83
- BZFD N/A
- AVG Volume (30 Days)
- MGNX 1.1M
- BZFD 315.4K
- Earning Date
- MGNX 05-08-2025
- BZFD 05-12-2025
- Dividend Yield
- MGNX N/A
- BZFD N/A
- EPS Growth
- MGNX N/A
- BZFD N/A
- EPS
- MGNX N/A
- BZFD N/A
- Revenue
- MGNX $149,962,000.00
- BZFD $189,887,000.00
- Revenue This Year
- MGNX N/A
- BZFD $89.62
- Revenue Next Year
- MGNX $80.86
- BZFD $4.50
- P/E Ratio
- MGNX N/A
- BZFD N/A
- Revenue Growth
- MGNX 155.26
- BZFD N/A
- 52 Week Low
- MGNX $0.99
- BZFD $1.26
- 52 Week High
- MGNX $17.24
- BZFD $5.68
- Technical
- Relative Strength Index (RSI)
- MGNX 34.84
- BZFD 37.09
- Support Level
- MGNX $1.10
- BZFD $1.65
- Resistance Level
- MGNX $1.34
- BZFD $1.79
- Average True Range (ATR)
- MGNX 0.13
- BZFD 0.15
- MACD
- MGNX 0.04
- BZFD -0.02
- Stochastic Oscillator
- MGNX 77.14
- BZFD 15.25
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About BZFD BuzzFeed Inc.
BuzzFeed Inc is a tech-powered, diversified media company that reaches hundreds of millions globally through its cross-platform news and entertainment network. The company produces articles, lists, quizzes, videos, and original series; lifestyle content through brands including Tasty, social food network; original reporting and investigative journalism through BuzzFeed News and HuffPost; an industry- affiliate business, strategic partnerships, licensing and product development through BuzzFeed Commerce; and original productions across broadcast, cable, SVOD, film and digital platforms for BuzzFeed Studios.